LECTURERS

 

 

 

Jesus G. Berdeja, MD Director, Multiple Myeloma Research Greco-Hainsworth Centers for Cancer Research Tennessee Oncology Nashville, Tennessee

Jesus G. Berdeja received his undergraduate degree from Stanford University and medical degree from Harvard University.  He completed his internship and residency in the Department of Internal Medicine at the University of California in San Francisco and fellowships in medical oncology and hematology at Johns Hopkins University School of Medicine in Baltimore.  Dr. Berdeja specializes in clinical hematology, with a focus on multiple myeloma. Additionally, he is an active member of several professional organizations, including the International Myeloma Society, the American Society of Clinical Oncology, the American Society of Hematology, the International Myeloma Working Group and the Clinical Trials Myeloma Intergroup Committee. An active researcher, Dr. Berdeja has been the principal investigator many funded clinical trials in the field of multiple myeloma.

He has published extensively in the peer-reviewed literature and is a frequent invited lecturer. 

 

 

 

Michel Delforge University of Leuven, Leuven, Belgium

Michel Delforge, MD, PhD, is professor of medicine in the department of hematology at the University of Leuven, in Leuven, Belgium. He studied medicine at the University of Leuven, where he obtained a doctoral degree in biomedical sciences. He continued his medical training as a research fellow at the University of Minnesota, Minneapolis, MN, USA, and subsequently undertook a clinical fellowship at the University of Leuven, with specific interests in myelodysplastic syndromes and plasma cell diseases.

Professor Delforge is clinical head of the department of hematology at the University Hospital Leuven. He directs the plasma cell dyscrasia unit with major focus on clinical trials with novel agents and with a specific interest in novel therapies and supportive care. He is the current chair of the myeloma committee of the Belgian Hematology Society and a senior clinical investigator and holds the Fraiture chair in hematology. From 2017 till 2025 he was the director of the Leuven Cancer Institute.

He has authored and co-authored more than 250 articles in peer-reviewed medical journals and several book chapters in the field of hematology

 

 

Thierry FACON, MD

Lille University Hospital, Lille, France and French Academy of Medicine, Paris, France. Thierry Facon, MD, is Professor of Haematology in the Department of Haematology, Lille University Hospital, Lille, France, a position he has held since 2000. He is a Member of the French National Academy of Medicine, and General Secretary of the Foundation of the French National Academy of Medicine. He currently serves as a member of the Transparency Committee of the French National Authority for Health.

Professor Facon was President of the French Society of Hematology between 2021 and 2024 and President of the Intergroupe Francophone du Myélome (IFM) between 2003 and 2006. He has presented at several international congresses, including the Plenary session at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2006, the Plenary sessions at the annual meeting of the American Society of Hematology (ASH) in 2013 and 2018, the Plenary Session at the annual meeting of the European Haematology Association (EHA) in 2024. He also presented at the Educational sessions of EHA 2008 and 2014, and the Educational sessions of ASH in 2015 and 2018. He co-organized the XIIIth International He is an Honorary Professor at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, China since 2015 Myeloma Workshop (IMW) in Paris in 2011, and is a member of the American Society of Hematology (ASH), the European Haematology Association (EHA), the International Myeloma Working Group (IMWG), and the International Myeloma Society (IMS). He serves currently as Associate Editor of Leukemia, and is a founder member and administrator of the Fondation Française pour la Recherche contre le Myélome et les Gammapathies (FFRMG) under the aegis of the Fondation de France whose main objective is to enable scientists and
students to carry out research programs in host laboratories in France or abroad. He is a co-organizer of the myeloma international COMY meeting.

He has presented the “Pierre Stryckmans Memorial Lecture” of the Belgian Hematological Society in 2015. He received the Joseph Michaeli Award from Weill Cornell Medicine, New York, USA, for his contributions to the treatment of Myeloma Research, and the Saint Antoine EBMT achievement Award in 2017. He received the Robert Kyle career achievement Award in 2020 and the Waldenstrom Life Time Achievement Award from the International Myeloma Society in 2024. He is an Honorary Professor at the Institute of Hematology &
Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, China since 2015. Professor Facon is author and co-author of a number of articles and has published his work in various prestigious international journals including, as first or senior author, The Lancet, Nature Medicine, and The New England Journal of Medicine.

   

 

Dr Laurent Garderet, Pitié Salpêtrière Hospital in Paris, France

Dr Laurent Garderet is a French hematologist working in the hematology department at Pitié Salpêtrière Hospital in Paris, France. He did his medical studies as well as his training in Paris. He also did a post-doctoral internship in the transplant department of the M.D Anderson Cancer Center in Houston under the supervision of Dr Richard Champlin. His main interestsfocus on myeloma treatment and biology.
He is a board member of the  Intergroupe Francophone du Myélome and the past chairman of the Plasma Cell D of the EBMT Chronic Malignancies Working Party. He is also a member of the International Myeloma Society (IMS) as well as the International Kidney Monoclonal Gammopathy (IKMG) research group.
He is currently the World Bone Marrow Transplantation society (WBMT) treasurer and co-chair of the CAR T subcommittee of the EBMT CMWP.

 

Prof Alessandro Gozzetti

Prof Alessandro Gozzetti gained his medical degree in 1993 and hematology fellowship in 1997 from Bologna University, Italy and completed a PhD in Oncology in 2001. He worked as research fellow 3 years at the University of Chicago at the Molecular Cytogenetic
Cancer Center lab led by Dr Janet Rowley and Michelle Le Beau and discovered new translocations using fluorescence in situ hybridization in non-Hodgkin lymphomas, CLL and myeloma (Cancer Research, 2000)

He is Associate Professor of Hematology at the Division of Hematology of University of Siena since 2018. Prof. Gozzetti is Director of the Multiple Myeloma program at the University of Siena and Director of the Hematology Specialization School since 2020.
He participated in several multiple myeloma trials as PI and was in the writing committee in many of them. He led national research on CNS myeloma (Cancer 2012) and a multicenter phase 2 trial in Multiple Myeloma on Daratumumab as consolidation therapy in
patients MRD positive by next-generation flow that was recently published (DART4MM, Br J Hematol 2026).

His Areas of interest are: Multiple Myeloma; MRD, hematological molecular cytogenetics. He is one of the founders of the Multiple Myeloma Tuscan Group (RTM) and member of the International Myeloma Working Group since 2016.
He is Member of Italian Society of Hematology (SIE) and Italian Society of Experimental Hematology (SIES), European Hematology Association (EHA), International Myeloma Society (IMS).

He published as author or coauthor over 250 papers in peer reviewed Journals and over 200 abstracts and 3 book chapters.

     

 

Jens Hillengass, Roswell Park Cancer Institute, Buffalo NY, USA

Jens Hillengass, MD, PhD, is Professor of Oncology and Vice Chair of Research of the Department of Medicine at Roswell Park Cancer Institute in Buffalo, NY and Professor of Internal Medicine at the University at Buffalo.
Prior to joining Roswell Park, he was the deputy of the section multiple myeloma of the University Hospital of Heidelberg, Germany, the leader of its autologous stem cell transplantation program, and head of the hemato-oncological imaging research group at the German Cancer Research Center (DKFZ).

He completed his medical degree at Heidelberg University, where he later completed residency and fellowship in the department of hematology, oncology, and rheumatology. Dr Hillengass received a Gerok scholarship to study radiology at the German Cancer Research Center. Additionally, he completed a research fellowship at the National Cancer Institute.

Dr. Hillengass is member of the International Myeloma Working Group where he co-chairs thebone and  imaging group. He is also co-chair of the myeloma committee of the Alliance for Clinical Trials.

 

Michaela Hillengass 



Curriculum vitae
Personal Information Date of Birth: August 7th 1974
Place of Birth: Karlsruhe, Germany
Nationality: German
Marital status: Married to Jens Hillengass MD
Education 1981-1985 Primary School, Linkenheim, Germany
1985-1991 Secondary School, Linkenheim, Germany
Oct. 1991-Mar.1992 Biblical diaconical Seminary
Apr.1992-Mar.1995 nurse´s training school

(Diakonissenkrankenhaus, Hospital, Karlsruhe
Germany)

Professional Experience 1995-1998 trauma surgical ward
(Diakonissenkrankenhaus, Karlsruhe
Germany)
1998 anesthesia nursing

(Diakonissenkrankenhaus, Karlsruhe,
Germany)
1999-2000 ophthalmic clinic

(Diakonissenkrankenhaus, Karlsruhe,
Germany)

2000-2004 otorhinolaryngology clinic (head nurse)
(Diakonissenkrankenhaus, Karlsruhe,
Germany)

2005 surgical ward/ geriatric rehabilitation
(Diakonissenkrankenhaus, Karlsruhe,
Germany)
2005-2006 sabbatical
2006-2007 oncological day clinic (National Center for

Tumor Diseases, Heidelberg, Germany)
2007-2013 hematological day clinic (University

Hospital, Heidelberg, Germany)

2012 study documentation (National Institutes of

Health, Bethesda, MD)

2013-2017 Case Manager Outpatient Clinic, Autologeous

Stem Cell Transplant Clinic

July 2018-July 2019 Clinical Research Associate, Roswell Park

Comprehensive Cancer Center
Since Dec. 2019 Exercise Trainer/Research Coordinator,
Roswell Park Comprehensive Cancer Center

Qualifications 1996 nurse mentoring course
2001 qualification as head nurse
2010 training as pain nurse
2014 Fitness trainer C license (certified)
2015 Case Manager
October, 9 th 2019 ACSM Certified Personal Trainer
April 2026 ACSM Certified Cancer Exercise Specialist
Memberships 2018 associate member International Myeloma

Foundation Nursing Leadership Board
Clinical trials (patient monitoring) CapRI (Pancreatic Cancer), Crystal Study
(Colorectal Cancer), GMMG-HD4 and –MM5
study, ELOQUENT-1/-2, BHQ880 (Multiple
Myeloma), PERLL study (Lymphoma), GHSG
HD16, HD17 study (Hodgkins Lymphoma)
Clinical trials (data management) A Randomized Phase III Study Comparing
Conventional Dose Treatment Using a
Combination of Lenalidomide, Bortezomib and
Dexamethasone (RVD) to High-Dose Treatment
with Peripheral Stem Cell Transplant in the
Initial Management of Myeloma in Patients up
to 65 Years of Age- Closed with Treatment,
(H125001) An Open-Label Phase 1 / 2 Study of
JCARH125, BCMA targeted Chimeric Antigen
Receptor (CAR) T Cells, in Subjects with
Relapsed and/or Refractory Multiple Myeloma,
Phase I/II Study of Carfilzomib plus Rituximab
plus Ifosfamide plus Carboplatin plus
Etoposide (C-R-ICE) in Patients with
Relapsed/Refractory Diffuse Large B-cell
Lymphoma (DLBCL)
Languages German (native language)

English (good)
French (basic level)Publications

Original manuscipts
Maatouk I, He S, Hummel M, Hemmer S, Hillengass M, Goldschmidt H, Hartmann M, Herzog W, Hillengass J. Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma. Blood Cancer J. 2019 Jan 21;9(2):9. doi: 10.1038/s41408- 019-0172-1. No abstract available.

Maatouk I, He S, Becker N, Hummel M, Hemmer S, Hillengass M, Goldschmidt H, Hartmann M, Schellberg D, Herzog W, Hillengass J. Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study. BMJ Open. 2018 Jul 30;8(7):e021376. doi: 10.1136/bmjopen-2017-021376. Mai EK, Hielscher T, Kloth JK, Merz M, Shah S, Hillengass M, Wagner B, Hose D, Raab MS, Jauch A, Delorme S, Goldschmidt H, Weber MA, Hillengass J. Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology. Eur Radiol. 2016 Nov;26(11):3939-3948. Epub 2016 Jan 15.

Mai EK, Hielscher T, Kloth JK, Merz M, Shah S, Raab MS, Hillengass M, Wagner B, Jauch A, Hose D, Weber MA, Delorme S, Goldschmidt H, Hillengass J. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. Haematologica. 2015 Jun;100(6):818-25. doi: 10.3324/haematol.2015.124115. Epub 2015 Mar 20.

Presentations
Hillengass M, Hillengass J, He S, Maathouk I, Hemmer S. Physical exercise habits of patients with multiple myeloma. International Myeloma Workshop, 2017, New Delhi, India

 

     

 

Artur Jurczyszyn, MD, PhD
Professor of Medicine
Head of the Plasma Cell Dyscrasias Center
Jagiellonian University Medical College, Kraków, Poland

Artur Jurczyszyn is Professor of Medicine at the Department of Hematology, Jagiellonian University Medical College, and Head of the Plasma Cell Dyscrasias Center in Kraków, Poland. A specialist in hematology and internal medicine, he combines three decades of clinical experience with research dedicated to improving outcomes for patients with multiple myeloma and related disorders.

His research focuses particularly on rare and aggressive presentations of plasma cell malignancies, including plasma cell leukemia, extramedullary disease, central nervous system involvement, and myeloma in young adults. Through international, multicenter collaborations, he has contributed to studies advancing the understanding of these challenging conditions and their prognostic factors. He has authored or co-authored more than 250 scientific publications and served as scientific editor of monographs on clinical hematology.

Professor Jurczyszyn graduated from the Jagiellonian University in 1996, received his PhD in 2003, completed his habilitation in 2016, and was awarded the title of Professor of Medical and Health Sciences in 2021. In 2025, he was elected a Corresponding Member of the Polish Academy of Arts and Sciences.

He is a member of the International Myeloma Working Group, the International Myeloma Society, the European Hematology Association, and the American Society of Hematology. His distinctions include the Tadeusz Browicz Award of the Polish Academy of Arts and Sciences and national ministerial awards for scientific achievement.

Beyond his academic and clinical work, he is co-founder and President of the Myeloma Treatment Center Foundation, established in 2008. Through its educational, publishing, rehabilitation, and patient-support initiatives, he promotes comprehensive care that addresses both the medical and everyday challenges of living with myeloma. His work brings together scientific rigor, international collaboration, and a sustained commitment to patients and their families.

 

 

Gabor Mikala 

Gabor Mikala is presently a Hematology Division Head at the Department of Internal Medicine and
Hematology at Semmelweis University, Budapest, Hungary. Previously, he served as Division Head for
Myeloma and Lymphoma Therapy at the National Institute for Hematology and Infectious Diseases in
Budapest, and held a joint appointment as professor of Anatomy, Physiology, and Cell Biology at
Semmelweis University.

He received his PhD for his research work at the Institute of Molecular Pharmacology and Biophysics
at the University of Cincinnati, USA. For the last 30 years, his major scientific interest has been the
biology and ever-evolving therapeutic landscape of multiple myeloma. He heads the Myeloma
Working Group of the Hungarian Society of Hematology and represents Hungary in the International
Myeloma Working Group.